Buyer beware, Pg6

Key Highlights:

• The Health Ministry expanded Schedule H2 drugs to entire therapeutic classes, shifting regulation from revenue to risk-based.
• This mandates a barcode or QR code on each pack of specific drugs for authenticity verification.
• The system aims to track defective batches and combat counterfeit medicines, particularly vaccines, cancer drugs, and antimicrobials.
• The move seeks to address international concerns from the U.S. FDA, European Medicines Agency, and U.S. Trade Representative regarding India's pharmaceutical quality control.

Schedule H2.png

Detailed Insights:

• Schedule H2 was initially introduced in 2022-23 for a curated list of brands, requiring a QR code for authenticity.
• The expanded framework includes encoding product identifiers, manufacturing license numbers, and batch details to enhance traceability.
• Counterfeit drugs contribute to high antimicrobial resistance rates in India by leading to sub-therapeutic dosing.
• The Narcotics Control Bureau has raised concerns about medicinal opioids and psychotropic substances entering illicit markets.
• The new system, alongside the Jan Vishwas Act 2026, distinguishes between procedural and substantial non-compliance for more effective enforcement.
• Successful implementation requires a state-managed database, interoperable software, scanning infrastructure, and consumer verification habits.
• The new packaging and IT integration requirements pose a significant strain on MSME manufacturers.
• Handling sensitive prescription data for controlled substances necessitates a robust digital governance layer.

Key Concepts Involved:

• Schedule H2: A category of drugs in India requiring specific packaging and authentication measures like QR codes to ensure genuineness.
• Antimicrobial Resistance (AMR): The ability of microorganisms to withstand antimicrobial treatments, making infections harder to treat.
• Jan Vishwas Act 2026: Legislation aimed at decriminalizing minor offenses and rationalizing penalties across various laws, distinguishing between procedural and substantial non-compliance.